Renaissance Technologies LLC acquired a new stake in shares of Tyra Biosciences, Inc. (NASDAQ:TYRA - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 29,100 shares of the company's stock, valued at approximately $404,000. Renaissance Technologies LLC owned about 0.06% of Tyra Biosciences at the end of the most recent quarter.
Several other hedge funds also recently bought and sold shares of the company. KLP Kapitalforvaltning AS acquired a new stake in shares of Tyra Biosciences during the 4th quarter valued at about $31,000. US Bancorp DE acquired a new stake in Tyra Biosciences in the fourth quarter valued at approximately $50,000. Wells Fargo & Company MN grew its position in Tyra Biosciences by 51.7% in the fourth quarter. Wells Fargo & Company MN now owns 9,493 shares of the company's stock worth $132,000 after acquiring an additional 3,236 shares in the last quarter. Russell Investments Group Ltd. increased its stake in shares of Tyra Biosciences by 130,587.5% during the 4th quarter. Russell Investments Group Ltd. now owns 10,455 shares of the company's stock worth $145,000 after purchasing an additional 10,447 shares during the last quarter. Finally, China Universal Asset Management Co. Ltd. bought a new position in shares of Tyra Biosciences during the 4th quarter valued at $149,000. 84.14% of the stock is owned by institutional investors and hedge funds.
Tyra Biosciences Stock Performance
NASDAQ TYRA opened at $10.86 on Monday. The stock has a 50-day simple moving average of $9.80 and a 200 day simple moving average of $13.73. The stock has a market capitalization of $576.56 million, a PE ratio of -6.75 and a beta of 1.19. Tyra Biosciences, Inc. has a twelve month low of $6.42 and a twelve month high of $29.60.
Tyra Biosciences (NASDAQ:TYRA - Get Free Report) last announced its quarterly earnings data on Thursday, March 27th. The company reported ($0.43) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.05. As a group, equities research analysts forecast that Tyra Biosciences, Inc. will post -1.57 EPS for the current fiscal year.
Insiders Place Their Bets
In related news, Director Nina S. Kjellson sold 5,401 shares of the stock in a transaction dated Wednesday, February 5th. The shares were sold at an average price of $13.76, for a total value of $74,317.76. Following the completion of the sale, the director now owns 443,885 shares in the company, valued at approximately $6,107,857.60. This trade represents a 1.20 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 15.40% of the company's stock.
Wall Street Analyst Weigh In
A number of equities research analysts recently issued reports on the stock. UBS Group began coverage on shares of Tyra Biosciences in a report on Tuesday, January 7th. They issued a "buy" rating and a $28.00 price objective for the company. HC Wainwright reissued a "buy" rating and set a $30.00 price objective on shares of Tyra Biosciences in a report on Monday, March 31st. Finally, Wedbush reissued an "outperform" rating and issued a $30.00 price objective on shares of Tyra Biosciences in a research note on Friday, March 28th. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus price target of $30.83.
Check Out Our Latest Analysis on TYRA
Tyra Biosciences Company Profile
(
Free Report)
Tyra Biosciences, Inc, a clinical-stage biotechnology company, develops precision medicines for fibroblast growth factor receptor (FGFR) biology in the United States. The company offers SNÅP, a precision medicine platform that enables drug design through iterative molecular snapshots to predict genetic alterations for developing therapies targeting oncology and genetically defined conditions.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Tyra Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tyra Biosciences wasn't on the list.
While Tyra Biosciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Need to stretch out your 401K or Roth IRA plan? Use these time-tested investing strategies to grow the monthly retirement income that your stock portfolio generates.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
